This Pre-IPO offering outlines the opportunities for the commercialisation of novel formulations of HOCL in the healthcare and pharmaceutical markets. Specifically how the SpectrumX Group can positively impact these sectors, through a diversified portfolio of offerings, by exploiting licenses from Spectrum Antimicrobials Inc., of the world’s first and only patent-protectable formulations of HOCL (Hypochlorous Acid).
The company is focused on bringing to market a groundbreaking respiratory therapy (SPC-069) and the roll out of the most powerful hand sanitiser in the world (Spectricept™). Both products utilise unique patent pending HOCL formulations.
HOCL is naturally occurring in human’s white blood cells and is a key contributor to mankind’s evolution and protection over millions of years. It is human safe whilst also being the most effective disinfectant known to mankind.
REQUEST INVESTMENT OFFERING HERE